Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

How diseases became "genetic".

Löwy I.

Cien Saude Colet. 2019 Sep 26;24(10):3607-3617. doi: 10.1590/1413-812320182410.19102019. eCollection 2019.

2.

Tumor-reprogrammed resident T cells resist radiation to control tumors.

Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR.

Nat Commun. 2019 Sep 2;10(1):3959. doi: 10.1038/s41467-019-11906-2.

3.

Re-imagining global health through social medicine.

Adams V, Behague D, Caduff C, Löwy I, Ortega F.

Glob Public Health. 2019 Oct;14(10):1383-1400. doi: 10.1080/17441692.2019.1587639. Epub 2019 Mar 19.

PMID:
30887910
4.

The birthing house as a place for birth: contextualizing the Rio de Janeiro birthing house.

Löwy I.

Hist Cienc Saude Manguinhos. 2018 Oct-Dec;25(4):1161-1169. doi: 10.1590/S0104-59702018000500014.

5.

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.

Colston E, Grasela D, Gardiner D, Bucy RP, Vakkalagadda B, Korman AJ, Lowy I.

PLoS One. 2018 Jun 7;13(6):e0198158. doi: 10.1371/journal.pone.0198158. eCollection 2018.

6.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

7.

Zika and Aedes aegypti: new and old challenges.

Bueno FTC, García M, Moya J, Löwy I, Benchimol JL, Cerqueira RC, Cueto M.

Hist Cienc Saude Manguinhos. 2017 Oct-Dec;24(4):1161-1180. doi: 10.1590/S0104-59702017000500017. Portuguese, English.

8.

Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma.

Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, Fury M.

Oncologist. 2018 Jan;23(1):118-120. doi: 10.1634/theoncologist.2017-0344. Epub 2017 Nov 20.

9.

Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.

Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q, D'Orvilliers A, Garnova E, Rafique A, Poueymirou W, Martin J, Huang T, Skokos D, Kantrowitz J, Popke J, Mohrs M, MacDonald D, Ioffe E, Olson W, Lowy I, Murphy A, Thurston G.

Mol Cancer Ther. 2017 May;16(5):861-870. doi: 10.1158/1535-7163.MCT-16-0665. Epub 2017 Mar 6.

10.

Leaking Containers: Success and Failure in Controlling the Mosquito Aedes aegypti in Brazil.

Löwy I.

Am J Public Health. 2017 Apr;107(4):517-524. doi: 10.2105/AJPH.2017.303652. Epub 2017 Feb 16.

11.

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.

Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG.

J Immunother Cancer. 2016 Nov 15;4:70. doi: 10.1186/s40425-016-0176-3. eCollection 2016.

12.

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P.

Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045. Review.

13.

THE BIOMEDICALIZATION OF BRAZILIAN BODIES: ANTHROPOLOGICAL PERSPECTIVES.

Löwy I, Sanabria E.

Hist Cienc Saude Manguinhos. 2016 Jan-Mar;23(1):11-8. doi: 10.1590/S0104-59702016000100002. English, Portuguese. No abstract available.

14.

Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade.

Eichten A, Su J, Adler AP, Zhang L, Ioffe E, Parveen AA, Yancopoulos GD, Rudge J, Lowy I, Lin HC, MacDonald D, Daly C, Duan X, Thurston G.

Cancer Res. 2016 Apr 15;76(8):2327-39. doi: 10.1158/0008-5472.CAN-15-1443. Epub 2016 Feb 26.

15.

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL.

Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21.

16.

How genetics came to the unborn: 1960-2000.

Löwy I.

Stud Hist Philos Biol Biomed Sci. 2014 Sep;47 Pt A:154-62. doi: 10.1016/j.shpsc.2014.05.015. Epub 2014 Jun 23.

PMID:
24968964
17.

Prenatal diagnosis: the irresistible rise of the 'visible fetus'.

Löwy I.

Stud Hist Philos Biol Biomed Sci. 2014 Sep;47 Pt B:290-9. doi: 10.1016/j.shpsc.2013.12.003. Epub 2014 Jan 17.

PMID:
24440137
18.

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, van den Eertwegh AJ, de Gruijl TD.

J Immunother Cancer. 2014 Sep 16;2:31. doi: 10.1186/s40425-014-0031-3. eCollection 2014.

19.
20.

Nivolumab plus ipilimumab in advanced melanoma.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M.

N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

21.

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.

Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I.

PLoS One. 2013 May 22;8(5):e63818. doi: 10.1371/journal.pone.0063818. Print 2013.

22.

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D'Adamo DR, Keohan ML, Wagner MJ, Scheu K, Chiu R, Ritter E, Kachel J, Lowy I, Old LJ, Ritter G.

Sarcoma. 2013;2013:168145. doi: 10.1155/2013/168145. Epub 2013 Feb 27.

23.
24.

Microscope slides in the life sciences: material, epistemic and symbolic objects.

Löwy I.

Hist Philos Life Sci. 2013;35(3):309-18. No abstract available.

PMID:
24779104
25.

The best possible intentions testing prophylactic approaches on humans in developing countries.

Löwy I.

Am J Public Health. 2013 Feb;103(2):226-37. doi: 10.2105/AJPH.2012.300901. Epub 2012 Dec 13.

26.

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD.

Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10.

PMID:
22878899
27.

Defusing the population bomb in the 1950s: foam tablets in India.

Löwy I.

Stud Hist Philos Biol Biomed Sci. 2012 Sep;43(3):583-93. doi: 10.1016/j.shpsc.2012.03.002. Epub 2012 May 10.

PMID:
22580021
28.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

PMID:
22326922
29.

"Because of their praiseworthy modesty, they consult too late": regime of hope and cancer of the womb, 1800-1910.

Löwy I.

Bull Hist Med. 2011 Fall;85(3):356-83. doi: 10.1353/bhm.2011.0058.

PMID:
22080796
30.
31.

Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.

Riddle V, Leese P, Blanset D, Adamcio M, Meldorf M, Lowy I.

Clin Vaccine Immunol. 2011 Dec;18(12):2136-42. doi: 10.1128/CVI.05059-11. Epub 2011 Oct 5.

32.
33.
34.

Martin Arrowsmith's clinical trial: scientific precision and heroic medicine.

Löwy I.

J R Soc Med. 2010 Nov;103(11):461-6. doi: 10.1258/jrsm.2010.10k038. No abstract available.

35.

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA.

J Immunother. 2010 Oct;33(8):828-33. doi: 10.1097/CJI.0b013e3181eec14c.

PMID:
20842054
36.

CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.

Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Chut T, Soiffer R, Mitrovich RC, Lowy I, Ball ED.

Biol Blood Marrow Transplant. 2011 May;17(5):682-92. doi: 10.1016/j.bbmt.2010.08.005. Epub 2010 Aug 14.

37.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL.

J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.

38.

Treatment with monoclonal antibodies against Clostridium difficile toxins.

Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S, Hay CA, Ambrosino DM.

N Engl J Med. 2010 Jan 21;362(3):197-205. doi: 10.1056/NEJMoa0907635.

39.

[Cultures of bacteriology in France, 1880-1900: bench and politics].

Löwy I.

Gesnerus. 2010;67(2):188-216. French.

PMID:
21425657
40.

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D.

Vaccine. 2010 Jan 22;28(4):965-9. doi: 10.1016/j.vaccine.2009.10.144. Epub 2009 Nov 24.

PMID:
19941990
41.

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM.

Clin Cancer Res. 2009 Oct 15;15(20):6446-53. doi: 10.1158/1078-0432.CCR-09-1339. Epub 2009 Oct 6.

42.

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.

Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED.

Blood. 2009 Feb 12;113(7):1581-8. doi: 10.1182/blood-2008-07-168468. Epub 2008 Oct 30.

43.

Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.

Taylor CP, Tummala S, Molrine D, Davidson L, Farrell RJ, Lembo A, Hibberd PL, Lowy I, Kelly CP.

Vaccine. 2008 Jun 25;26(27-28):3404-9. doi: 10.1016/j.vaccine.2008.04.042. Epub 2008 May 7.

44.

Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection.

Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai WP, Petrovas C, Fuchs D, Heraud JM, Venzon D, Shearer GM, Koup RA, Lowy I, Miller CJ, Franchini G.

J Immunol. 2008 Apr 15;180(8):5439-47.

45.

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10. doi: 10.1073/pnas.0712237105. Epub 2008 Feb 19.

46.

Fleck, anatomical drawings and early modern history.

Lowy I.

Med Secoli. 2008;20(3):745-66.

PMID:
19848216
47.

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA.

J Immunother. 2007 Nov-Dec;30(8):825-30.

48.
49.

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP.

Clin Cancer Res. 2007 Mar 15;13(6):1810-5.

50.

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.

O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE.

Clin Cancer Res. 2007 Feb 1;13(3):958-64.

Supplemental Content

Support Center